文献速递骨质疏松与钙磷/甲状旁腺

噻嗪类药物治疗原发性甲状旁腺功能亢进症——老药新适应证?

Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication?
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

氢氯噻嗪12.5~50 mg/d使平均尿钙从427±174 mg/d降至251±114 mg/d(P<0.001),甲状旁腺激素从115±57 ng/L降至74±36 ng/L(P<0.001),血钙无变化(10.7±0.4 mg/dL vs 10.5±1.2 mg/dL,P=0.4)。作者认为噻嗪类可控制高钙尿且可能降低甲状旁腺激素,但需密切监测高钙血症。

要点

  • 氢氯噻嗪12.5~50 mg/d使PHPT患者平均尿钙和甲状旁腺激素显著下降。
  • 治疗前后平均血钙无显著变化(10.7±0.4 mg/dL vs 10.5±1.2 mg/dL,P=0.4)。
  • 各剂量间尿钙下降幅度及血钙变化无差异;作者认为需密切监测高钙血症。

核心结论

  • 噻嗪类即使12.5 mg/d也可能有效、至50 mg/d可能安全地控制PHPT患者的高钙尿,并可能有利于降低血清甲状旁腺激素水平,但需要密切监测高钙血症。

研究设计与样本

  • 回顾性病历分析,比较每例患者噻嗪类给药前后的数据。
  • 地点为一家三级医院的内分泌门诊。
  • 共纳入14例男性和58例女性PHPT患者,均接受噻嗪类治疗。

主要发现

  • 氢氯噻嗪12.5~50 mg/d使平均尿钙从427±174 mg/d降至251±114 mg/d(P<0.001)。
  • 甲状旁腺激素从115±57 ng/L降至74±36 ng/L(P<0.001)。
  • 血钙从停药时10.7±0.4 mg/dL变为用药时10.5±1.2 mg/dL(P=0.4),无显著变化。
  • 各剂量间尿钙下降幅度及血钙变化无差异。

关键数值与推荐

  • 原文未报告推荐条款。

临床怎么用

  • 作者认为噻嗪类可考虑用于控制PHPT患者的高钙尿,但需密切监测高钙血症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There is no therapy for control of hypercalciuria in nonoperable patients with primary hyperparathyroidism (PHPT). Thiazides are used for idiopathic hypercalciuria but are avoided in PHPT to prevent exacerbating hypercalcemia. Nevertheless, several reports suggested that thiazides may be safe in patients with PHPT. OBJECTIVE: To test the safety and efficacy of thiazides in PHPT. DESIGN: Retrospective analysis of medical records. SETTING: Endocrine clinic at a tertiary hospital. PATIENTS: Fourteen male and 58 female patients with PHPT treated with thiazides. INTERVENTIONS: Data were compared for each patient before and after thiazide administration. MAIN OUTCOME MEASURES: Effect of thiazide on urine and serum calcium levels. RESULTS: Data are given as mean ± standard deviation. Treatment with hydrochlorothiazide 12.5 to 50 mg/d led to a decrease in mean levels of urine calcium (427 ± 174 mg/d to 251 ± 114 mg/d; P < 0.001) and parathyroid hormone (115 ± 57 ng/L to 74 ± 36 ng/L; P < 0.001), with no change in serum calcium level (10.7 ± 0.4 mg/dL off treatment, 10.5 ± 1.2 mg/dL on treatment, P = 0.4). Findings were consistent over all doses, with no difference in the extent of reduction in urine calcium level or change in serum calcium level by thiazide dose. CONCLUSION: Thiazides may be effective even at a dose of 12.5 mg/d and safe at doses of up to 50 mg/d for controlling hypercalciuria in patients with PHPT and may have an advantage in decreasing serum parathyroid hormone level. However, careful monitoring for hypercalcemia is required.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tsvetov G, Hirsch D, Shimon I, et al. Thiazide Treatment in Primary Hyperparathyroidism-A New Indication for an Old Medication? J Clin Endocrinol Metab. 2017. PMID: 28388724. doi:10.1210/jc.2016-2481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。